Decreased Loxl2 was also observed in WlsΔOB-OS bone tumors by IHC, regardless whether wls was inactivated preventively (at 3 weeks; Fig. 5c) or therapeutically (at 5 weeks; Supplementary information, Fig. S5a). This evidence concerns the gene LOXL2 and bone neoplasm.